Browse RPL23

Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00238 Ribosomal protein L14p/L23e
Function

-

> Gene Ontology
 
Biological Process GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay
GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0006364 rRNA processing
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006413 translational initiation
GO:0006606 protein import into nucleus
GO:0006610 ribosomal protein import into nucleus
GO:0006612 protein targeting to membrane
GO:0006613 cotranslational protein targeting to membrane
GO:0006614 SRP-dependent cotranslational protein targeting to membrane
GO:0006913 nucleocytoplasmic transport
GO:0016072 rRNA metabolic process
GO:0017038 protein import
GO:0019058 viral life cycle
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0019439 aromatic compound catabolic process
GO:0022613 ribonucleoprotein complex biogenesis
GO:0034470 ncRNA processing
GO:0034504 protein localization to nucleus
GO:0034655 nucleobase-containing compound catabolic process
GO:0042254 ribosome biogenesis
GO:0044033 multi-organism metabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0044744 protein targeting to nucleus
GO:0045047 protein targeting to ER
GO:0046700 heterocycle catabolic process
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0070972 protein localization to endoplasmic reticulum
GO:0072599 establishment of protein localization to endoplasmic reticulum
GO:0072657 protein localization to membrane
GO:0090150 establishment of protein localization to membrane
GO:1901361 organic cyclic compound catabolic process
GO:1902593 single-organism nuclear import
Molecular Function GO:0003735 structural constituent of ribosome
GO:0019843 rRNA binding
GO:0070180 large ribosomal subunit rRNA binding
Cellular Component GO:0005840 ribosome
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0015934 large ribosomal subunit
GO:0022625 cytosolic large ribosomal subunit
GO:0022626 cytosolic ribosome
GO:0030055 cell-substrate junction
GO:0044391 ribosomal subunit
GO:0044445 cytosolic part
> KEGG and Reactome Pathway
 
KEGG hsa03010 Ribosome
Reactome R-HSA-157279: 3' -UTR-mediated translational regulation
R-HSA-72737: Cap-dependent Translation Initiation
R-HSA-1643685: Disease
R-HSA-156842: Eukaryotic Translation Elongation
R-HSA-72613: Eukaryotic Translation Initiation
R-HSA-72764: Eukaryotic Translation Termination
R-HSA-72689: Formation of a pool of free 40S subunits
R-HSA-72706: GTP hydrolysis and joining of the 60S ribosomal subunit
R-HSA-74160: Gene Expression
R-HSA-5663205: Infectious disease
R-HSA-168254: Influenza Infection
R-HSA-168255: Influenza Life Cycle
R-HSA-168273: Influenza Viral RNA Transcription and Replication
R-HSA-156827: L13a-mediated translational silencing of Ceruloplasmin expression
R-HSA-6791226: Major pathway of rRNA processing in the nucleolus and cytosol
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-392499: Metabolism of proteins
R-HSA-975957: Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
R-HSA-975956: Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
R-HSA-927802: Nonsense-Mediated Decay (NMD)
R-HSA-156902: Peptide chain elongation
R-HSA-1799339: SRP-dependent cotranslational protein targeting to membrane
R-HSA-2408522: Selenoamino acid metabolism
R-HSA-2408557: Selenocysteine synthesis
R-HSA-72766: Translation
R-HSA-192823: Viral mRNA Translation
R-HSA-72312: rRNA processing
R-HSA-8868773: rRNA processing in the nucleus and cytosol
Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RPL23 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RPL23 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28783722MelanomaPromote immunity (T cell function); essential for immunotherapyIn addition, many genes without an established connection to the EFT were ranked amongst the top 20 enriched genes in this genome-scale analysis, such as SOX10, CD58, MLANA, PSMB5, RPL23 and APLNR. Fifteen genes showed significant resistance to T-cell-mediated cytolysis with at least 1 sgRNA in these cells.; MART-1+ Mel624 cells with sgRNAs targeting each of the 9 candidate genes showed increased resistance against these T cells (Extended Data Fig. 6b, P < 0.05). The genes that we validated across different melanoma cell lines and different antigen–TCR combinations include cellular cytoskeleton genes, COL17A1 (collagen type XVII alpha 1) and TWF1 (twinfilin-1), a microRNA (hsa-mir-101-2) and a 60S ribosomal subunit (RPL23, Supplementary Discussion).
Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RPL23 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 1.03 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RPL23 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6490.0309
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.7430.882
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.570.881
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2640.525
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2010.937
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8540.799
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1920.747
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3940.883
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0021
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1330.969
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1430.979
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1730.0381
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RPL23. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RPL23. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RPL23.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RPL23. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RPL23 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RPL23 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRPL23
Nameribosomal protein L23
Aliases
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RPL23 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting RPL23.
ID Name Drug Type Targets #Targets
DB02494Alpha-Hydroxy-Beta-Phenyl-Propionic AcidSmall MoleculeCPA1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, ......14
DB07374AnisomycinSmall MoleculeRPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, ......13
DB08437PuromycinSmall MoleculeRPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, ......12